The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 13, 2018

Filed:

Jun. 08, 2016
Applicants:

Whitehead Institute for Biomedical Research, Cambridge, MA (US);

Massachusetts Institute of Technology, Cambridge, MA (US);

Inventors:

David M. Sabatini, Cambridge, MA (US);

Kivanc Birsoy, Cambridge, MA (US);

Matthew George Vander Heiden, Belmont, MA (US);

Lucas Bryan Sullivan, Boston, MA (US);

Dan Yi Gui, Cambridge, MA (US);

Assignees:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/198 (2006.01); A61K 31/194 (2006.01); A61K 31/52 (2006.01); A61K 38/00 (2006.01); A61K 31/19 (2006.01); A61K 31/505 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/198 (2013.01); A61K 31/19 (2013.01); A61K 31/194 (2013.01); A61K 31/505 (2013.01); A61K 31/52 (2013.01); A61K 38/00 (2013.01); A61K 45/06 (2013.01);
Abstract

Provided herein are methods, compositions, and systems for treating mitochondrial disorders (e.g., MERRF, MELAS, Kearns-Sayre syndrome, chronic progressive external ophthalmoplegia, diabetes mellitus and deafness, lactic acidosis, Leber's hereditary optic neuropathy, Wolff-Parkinson-White syndrome, Leigh syndrome, NARP, myoneurogenic gastrointestinal encephalopathy, mitochondrial DNA depletion syndrome) or neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease) by administering aspartate, or an analog or prodrug thereof, or an agent that increases intracellular levels of aspartate. Pharmaceutical compositions and kits for use in treating mitochondrial disorders and neurodegenerative diseases are also described herein. Also provided are methods for treating disease by modulating the redox state of a cell, and methods of treating a proliferative disease by administering a cytosolic aspartate aminotransferase (GOT1) inhibitor.


Find Patent Forward Citations

Loading…